Impact of baseline CD4+ T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: A prospective, multicentric study

Chinese Medical Journal

Volumn 122, Issue 20, 2009, Pages 2497-2502

  Liu, Zheng Yin ^a   Guo, Fu Ping ^a   Han, Yang ^a   Qiu, Zhi Feng ^a   Zuo, Ling Yan ^a   Li, Yan Ling ^a   Li, Tai Sheng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Acquired immunodeficiency syndrome; CD4+ T cell counts; Highly active antiretroviral therapy; Human immunodeficiency virus; Nevirapine

Indexed keywords

DIDANOSINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CD4 LYMPHOCYTE COUNT; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNE RESPONSE; LIPODYSTROPHY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; PROSPECTIVE STUDIES;

EID: 70350733826     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.20.018     Document Type: Article

References (23)

1. +T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
2. Clumeck N, Pozniak A, Raffi F. European guidelines for the clinical management and treatment of HIV infected adults in Europe. HIV Med 2008; 9: 65-131.
3. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and dolescents. (2007). (Accessed ON January 7, 2008 at http://aidsinfo.nih.gov//guidelines.)
4. Lederman MM, McKinnis R, Kelleher D, Cutrell A, Mellors J, Neisler M, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000; 14: 2635-2642. (Pubitemid 32118716)
5. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286: 2568-2577. (Pubitemid 33096808)
6. 6/L. AIDS 2002; 16: 1371-1381.
7. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003; 17: 711-720.
8. + T cell count. J Acquir Immune Defic Syndr 2004; 36: 702-713.
9. Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, Braitstein P, et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005; 40: 288-293. (Pubitemid 41533068)
10. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44: 441-446.
11. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μl in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41: 361-372. (Pubitemid 41022115)
12. Division of AIDS table for grading the severity of adult and pediatric adverse events (2004). (Accessed May 7, 2007 at http://rcc.tech-res.com/tox- tables.htm.)
13. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730. (Pubitemid 28534954)
14. Kumarasamy N, Solomon S, Chaguturu SK, Cecelia AJ, Vallabhaneni S, Flanigan TP, et al. The changing natural history of and after the introduction of generic antiretroviral HIV disease: before therapy in southern India. Clin Infect Dis 2005; 41: 1525-1528. (Pubitemid 41580000)
15. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48: 350-361
16. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4: 208-214. (Pubitemid 28137376)
17. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163: 2187-2195. (Pubitemid 37248783)
18. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 1907-1915. (Pubitemid 37070276)
19. + T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006; 194: 29-37.
20. Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis 2007; 44: 749-754. (Pubitemid 46272989)
21. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Medicine 2003; 4: 255-262. (Pubitemid 36949882)
22. van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, et al. The effect of baseline CD4 cell count and HIV-1 viralload on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19: 463-471. (Pubitemid 40515849)
23. Li T, Dai Y, Kuang J, Jiang J, Han Y, Qiu Z, et al. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. PLoS ONE 2008; 3: e3918.